Overview

Also Known As:MDR2 KO

MDR2 KO (Abcb4 or ATP-binding cassette, sub-family B (MDR/TAP), member 4) mice fail to secrete phospholipid into the bile from the liver. Mice develop portal inflammation followed by hepatocellular carcinoma. This strain may be useful in studies of intrahepatic cholestasis and liver cancer.

Donating Investigator

Dr. Piet Borst, The Netherlands Cancer Institute

Genetic overview

Genetic Background	Generation
	N10+pN1F3 (2019-03-01 00:00:00)

Abcb4^tm1Bor

Allele Type	Gene Symbol	Gene Name
Targeted (Null/Knockout)	Abcb4	ATP-binding cassette, sub-family B (MDR/TAP), member 4

View Genetics

Research Applications

Cancer Research
Metabolism Research
Internal/Organ Research
Research Tools

View All Research Applications

Base Price

Starting at:

$255.00 Domestic price for female 4-week

View Price List

Details

Important Note

This strain is homozygous for the retinal degeneration allele Pde6b^rd1.

Detailed Description

The Abcb4 (ATP-binding cassette, sub-family B (MDR/TAP), member 4) or MDR2 gene encodes a membrane protein that functions as a transporter using phosphatidylcholine as its substrate. MDR2 knock-out (KO) mice lack the ability to secrete phospholipid into the bile from the liver. Homozygotes develop a degenerative liver disease (additional details below). Portal inflammation ensues at an early age followed by hepatocellular carcinoma development after the age of 1 year.
In 1995, the donating investigator reported that homozygotes exhibit liver degeneration beginning around 8 months of age. In 2019, The Jackson Laboratory live colony also observes some incidence of sickly (jaundice) homozygotes as early as 4-5 months of age, and this occurs more frequently in females than males.
Bile from heterozygous mice has half the level of phospholipid when compared to bile from homozygotes. No liver pathology has been shown in heterozygotes.

Development

This strain was developed in the lab of Dr. Piet Borst at The Netherlands Cancer Institute in Amsterdam. The targeting vector was designed to replace exons 1 and 2 of the ATP-binding cassette, sub-family B (MDR/TAP), member 4 locus (Abcb4; MDR2) with a neomycin selection cassette. The translation initiation site is in exon 2. RNase protection assays indicated that mutant truncated transcripts are produced from this allele that contain exons 3-6 or 4-6. The construct was electroporated into 129P2/OlaHsd-derived E14 embryonic stem (ES) cells. Correctly targeted ES cells were injected into blastocysts and chimeric animals were bred to FVB/N mice. The resulting mice were backcrossed to FVB/N for at least five generations, and then sent to The Jackson Laboratory Repository in 1996. Upon arrival, the colony was additionally backcrossed to FVB/NJ inbred mice (Stock No. 001800). In 2019, the MDR2 KO colony is a total of at least ten generations onto FVB/N.

Control Suggestions

001800 FVB/NJ

Additional Information

Considerations for Choosing Controls

Selected References

Smit JJ; Schinkel AH; Oude Elferink RP; Groen AK; Wagenaar E; van Deemter L; Mol CA; Ottenhoff R; van der Lugt NM; van Roon MA; van der Valk MA; Offerhaus GJ; Berns AJ; Borst P. 1993. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75(3):451-62PubMed: 8106172 MGI: J:15531

View All References

Genetics

Abcb4^tm1Bor

Allele Symbol: Abcb4^tm1Bor

Allele Name	targeted mutation 1, Piet Borst
Allele Type	Targeted (Null/Knockout)
Allele Synonym(s)	mdr2-; mdr2^neo1; Mdr2ko; Pgy2^tm1Bor
Gene Symbol and Name	Abcb4, ATP-binding cassette, sub-family B (MDR/TAP), member 4
Gene Synonym(s)
Strain of Origin	129P2/OlaHsd
Chromosome	5
Molecular Note	A neomycin selection cassette replaced a genomic fragment containing exons 1 and 2. The translation initiation site is in exon 2. RNase proteiction assays indicated that mutant truncated transcripts are produced from this allele that contain exons 3-6 or 4-6.
Mutations Made By	Dr. Piet Borst, The Netherlands Cancer Institute

Disease/Phenotype

Disease Terms

Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).

cholecystitis

Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).

hepatocellular carcinoma

Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Cancer Research
- Increased Tumor Incidence
  - Hepatomas: hepatacellular carcinoma
  - Hepatomas

Genotype: Abcb4^tm1Bor related

Metabolism Research
Cancer Research
- Toxicology
Internal/Organ Research
- Liver Defects
Research Tools
- Toxicology Research

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N)

cardiovascular system phenotype

liver hemorrhage
- beginning at 4 to 6 months

immune system phenotype

bile duct inflammation
- inflammation of bile ducts

liver inflammation
- portal inflammation with mixed inflammatory infiltrate and slight fibrosis

liver/biliary system phenotype

abnormal bile canaliculus morphology
- bile canaliculi fail to mature remaining wide and smooth unlike in wild-type mice
- prominent widening and increased tortuosity of bile canaliculi with loss of microvilli is present

abnormal bile composition
- absence of phospholipid secretion in bile, lipid secretion is decreased and there is a 15-reduction in cholesterol secretion in bile
- chloride secretion is slightly, but significantly, elevated
- glutathione secretion in bile is ~14% of wild-type
- phospolipid to bile salt ratio is only ~41% of wild-type

abnormal bile duct morphology
- portal expansion due to ductular proliferation is seen

abnormal bile secretion

abnormal hepatobiliary system morphology

abnormal hepatobiliary system physiology

abnormal hepatocyte morphology
- hepatocyte degeneration, irregular size with nuclear polymorphism and focal necrosis are observed, along with increased proliferation

abnormal portal triad morphology
- at 3 months, mice exhibit expansion of the portal triad unlike in wild-type mice

bile duct inflammation
- inflammation of bile ducts

bile duct proliferation
- mice exhibit ductular proliferation and portal inflammation with mixed inflammatory infiltrate unlike in wild-type mice

biliary cirrhosis
- at 3 months, mice exhibit biliary cirrhosis with porto-portal fibrous septa unlike in wild-type mice

cholestasis

dilated bile duct
- larger bile ducts are dilated

enlarged liver
- beginning at 4 to 6 months

hepatic necrosis
- beginning at 4 to 6 months

increased hepatocellular carcinoma incidence
- beginning at 4 to 6 months, mice develop hepatocellular carcinoma with necrosis, hemorrhage, and strong cytonuclear polymorphism unlike in wild-type mice
- mice exhibit lung metastasis

intrahepatic cholestasis
- moderate liver damage with cholestatic properties (raised serum-conjugated bilirubin) is observed

liver hemorrhage
- beginning at 4 to 6 months

liver inflammation
- portal inflammation with mixed inflammatory infiltrate and slight fibrosis

cellular phenotype

hepatic necrosis
- beginning at 4 to 6 months

endocrine/exocrine gland phenotype

abnormal bile duct morphology
- portal expansion due to ductular proliferation is seen

bile duct proliferation
- mice exhibit ductular proliferation and portal inflammation with mixed inflammatory infiltrate unlike in wild-type mice

dilated bile duct
- larger bile ducts are dilated

neoplasm

increased hepatocellular carcinoma incidence
- beginning at 4 to 6 months, mice develop hepatocellular carcinoma with necrosis, hemorrhage, and strong cytonuclear polymorphism unlike in wild-type mice
- mice exhibit lung metastasis

reproductive system phenotype

reduced female fertility
- at 4 months

homeostasis/metabolism phenotype

abnormal blood homeostasis
- serum is yellowish, suggesting liver damage

abnormal circulating alanine transaminase level
- 5.8-fold increase in alanine transaminase level

abnormal circulating alkaline phosphatase level
- 3-fold increase in serum alkaline phosphatase level

abnormal circulating aspartate transaminase level
- 4-fold increase in aspartate transaminase level

abnormal circulating bilirubin level
- 12-fold elevated bilirubin level; ~50% of this is conjugated

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
involves: 129P2/OlaHsd * FVB/N

cellular phenotype

focal hepatic necrosis
- focal necrosis with formation of eosinophilic bodies

immune system phenotype

bile duct inflammation
- cholangitis

liver inflammation
- portal inflammation

liver/biliary system phenotype

abnormal hepatocyte morphology
- hepatocytes show irregular nuclear polymorphism

bile duct inflammation
- cholangitis

focal hepatic necrosis
- focal necrosis with formation of eosinophilic bodies

intrahepatic cholestasis

liver inflammation
- portal inflammation

digestive/alimentary phenotype

abnormal feces composition
- daily bile acid disposal in feces is decreased

abnormal intestine physiology
- mice exhibit an increase in taurocholic acid uptake in the ileum, indicating an increase in bile acid uptake
- sodium concentrations in the ileal lumen are increased

decreased intestinal cholesterol absorption
- 40% reduction in absorption efficiency

homeostasis/metabolism phenotype

abnormal circulating enzyme level

abnormal lipid homeostasis

abnormal sodium ion homeostasis
- sodium concentrations in the ileal lumen are increased

decreased circulating cholesterol level
- plasma levels reduced

decreased intestinal cholesterol absorption
- 40% reduction in absorption efficiency

increased bile salt level
- increase in concentration of bile acids in the plasma and the liver
- pool size of bile acids is increased

increased circulating alanine transaminase level

increased circulating aspartate transaminase level

increased circulating bilirubin level

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
C.129P2-Abcb4

homeostasis/metabolism phenotype

abnormal enzyme/coenzyme activity
- elevation in serum activities of liver enzymes, including aminotransferase and alkaline phosphatase

decreased circulating calcium level

decreased vitamin D level
- 25(OH)-vitamin D serum concentrations are almost 50% lower than in wild-type mice

increased alkaline phosphatase activity

increased circulating phosphate level

increased transforming growth factor level
- increase in serum levels of activated TGF-beta until the age of 30 weeks which subsequently declines to basal levels by 45 weeks of age compared to wild-type mice which show a continuous decrease throughout life

liver/biliary system phenotype

liver fibrosis
- liver damage increases most rapidly in the first 15 weeks of life and then progresses slowly thereafter

skeleton phenotype

abnormal bone remodeling
- mutants exhibit altered gene expression of bone modeling markers and an increase in serum levels of the osteoclastogenesis inducing factor RANKL, indicating impaired bone remodeling

abnormal compact bone morphology
- females exhibit a decrease in cortical bone density and a lower circumference of the bone at the exact mid-diaphysis (periosteal circumference), resulting in normal thickness of the cortical bone

abnormal trabecular bone morphology
- increase in trabecular separation at 20 weeks of age
- trabecular tissue mineral density is lower at 30 weeks of age
- with increasing age, changes in trabecular order and connectivity are seen with reduced mineralization of the trabecular bone meshwork

abnormal trabecular bone volume
- changes in trabecular bone volume fractions are seen at 5 weeks of age but not in older mice, however trabecular thickness does not differ from wild-type

decreased bone mineral content
- decrease in femoral mineral contents
- reduction of whole body bone mineral content in males and of bone fractions of the total tissue weights in females at 15 weeks of age

decreased bone mineral density
- females fed a vitamin D insufficient diet exhibit decreased femoral bone and cortical bone mineral density, compared to wild-type mice on the same diet
- vitamin D supplementation does not restore bone abnormalities

decreased bone trabecula number
- decrease in trabecular numbers at 20 weeks of age

decreased bone volume
- decrease in femoral mineral contents and in total femoral volume at 15 weeks of age, thus total femoral volume bone mineral density is not affected

decreased trabecular bone connectivity density
- connective density is lower at 20 weeks of age

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
involves: 129P2/OlaHsd * BALB/c

cardiovascular system phenotype

decreased systemic arterial systolic blood pressure
- mice treated with propranolol long-term show a minor reduction in the average systolic blood pressure without impact on viability

immune system phenotype

bile duct inflammation
- mice develop sclerosing cholangitis
- propranolol treatment reduces inflammation

liver/biliary system phenotype

bile duct inflammation
- mice develop sclerosing cholangitis
- propranolol treatment reduces inflammation

liver fibrosis
- after 5 months, septal formation and massive matrix deposition is seen around ducts in the liver and at 8 months, periportal fibrosis is frequently accompanied by septae formation and prominent proliferation of the bile ducts
- mice develop periportal fibrosis after 3 months of age, characterized by onion skin-like matrix formation around the bile ducts
- propranolol treatment improves liver architecture and reduces inflammation and fibrosis progression

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
CAnNCrl.12P2(FVB)-Abcb4

cardiovascular system phenotype

portal hypertension
- Background Sensitivity - mice on the BALB/cAnNCrl background show an earlier onset of severe portal hypertension than mice on the FVB/N background
- Background Sensitivity - portal pressure in mice on the BALB/cAnNCrl background increases at a higher pace compared to mice on the FVB/N background, peaking at 12 mmHg at 12 weeks compared to 8.2 mmHg in mice on the FVB/N background

liver/biliary system phenotype

increased hepatocellular carcinoma incidence
- liver tumors are classified as hepatocellular carcinoma
- Background Sensitivity - mice on the BALB/cAnNCrl background show accelerated development of primary liver cancer compared to mice on the FVB/N background, showing tumors starting at 7 months of age compared to 12 months of age on the FVB/N background
- Background Sensitivity - tumor burden in mice on the BALB/cAnNCrl background is higher than on the FVB/N background

liver cirrhosis
- Background Sensitivity - mice on the BALB/cAnNCrl background show accelerated development of cirrhosis compared to mice on the FVB/N background

liver fibrosis
- Background Sensitivity - collagen content in the liver of mice on the BALB/cAnNCrl background is higher at any time point studied compared to mice on the FVB/N background, with total hydroxyproline content about 3-fold higher in the liver than in mice on the FVB/N background
- Background Sensitivity - fibrotic matrix in mice on the BALB/cAnNCrl background is cross-linked to a greater degree than in mice on the FVB/N background
- Background Sensitivity - males exhibit more severe fibrosis than females
- Background Sensitivity - marker analysis indicates that fibrogenic cell activation is amplified in mice on the BALB/cAnNCrl background compared to the FVB/N background
- Background Sensitivity - mice on the BALB/cAnNCrl background show accelerated liver fibrosis compared to mice on the FVB/N background, with signs of bridging fibrosis already at 8 weeks and thick septae formation by 12 weeks
- mice spontaneously develop periductal onion-skin type fibrotic lesions starting from 4 weeks of age
- prominent sinusoidal fibrosis starting at 8 weeks of age

portal hypertension
- Background Sensitivity - mice on the BALB/cAnNCrl background show an earlier onset of severe portal hypertension than mice on the FVB/N background
- Background Sensitivity - portal pressure in mice on the BALB/cAnNCrl background increases at a higher pace compared to mice on the FVB/N background, peaking at 12 mmHg at 12 weeks compared to 8.2 mmHg in mice on the FVB/N background

neoplasm

increased hepatocellular carcinoma incidence
- liver tumors are classified as hepatocellular carcinoma
- Background Sensitivity - mice on the BALB/cAnNCrl background show accelerated development of primary liver cancer compared to mice on the FVB/N background, showing tumors starting at 7 months of age compared to 12 months of age on the FVB/N background
- Background Sensitivity - tumor burden in mice on the BALB/cAnNCrl background is higher than on the FVB/N background

growth/size/body region phenotype

weight loss
- mice lose weight at 12 months of age with a 21.5% reduction in weight compared to 2.9% in wild-type mice

hematopoietic system phenotype

enlarged spleen

homeostasis/metabolism phenotype

increased circulating alanine transaminase level
- increase in serum alanine aminotransferase is similar on both the BALB/cAnNCrl and FVB/N backgrounds

increased circulating alkaline phosphatase level
- Background Sensitivity - serum levels of alkaline phosphatase are higher on the BALB/cAnNCrl background and increase with age compared to mice on the FVB/N background which show a decrease in levels by 12 weeks

increased circulating aspartate transaminase level
- increase in serum aspartate aminotransferase is similar on both the BALB/cAnNCrl and FVB/N backgrounds

increased circulating bilirubin level
- Background Sensitivity - total bilirubin in serum of aged mice on the BALB/cAnNCrl background is higher at 7 months of age compared to mice on the FVB/N background, and continues to increase through 12 months of age

immune system phenotype

enlarged spleen

The following phenotype relates to a compound genotype created using this strain

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
FVB.129P2-Abcb4/J

cardiovascular system phenotype

portal hypertension
- Background Sensitivity - mice on the FVB/N background show a later onset of severe portal hypertension than mice on the BALB/cAnNCrl background
- Background Sensitivity - portal pressure in mice on the FVB/N background increases at a slower pace compared to mice on the BALB/cAnNCrl background

hematopoietic system phenotype

enlarged spleen

homeostasis/metabolism phenotype

abnormal circulating enzyme level
- elevated serum transaminase levels

increased circulating alanine transaminase level
- increase in serum alanine aminotransferase is similar on both the BALB/cAnNCrl and FVB/N backgrounds

increased circulating alkaline phosphatase level
- Background Sensitivity - serum levels of alkaline phosphatase are lower on the FVB/N background and show a decrease in levels by 12 weeks compared to mice on the BALB/cAnNCrl background in which levels increase with age

increased circulating aspartate transaminase level
- increase in serum aspartate aminotransferase is similar on both the BALB/cAnNCrl and FVB/N backgrounds

increased circulating bilirubin level
- slight increase
- Background Sensitivity - total bilirubin in serum of aged mice on the FVB/N background is lower at 7 months of age compared to mice on the BALB/cAnNCrl background

immune system phenotype

bile duct inflammation
- progressive sclerosing cholangitis

enlarged spleen

liver/biliary system phenotype

abnormal bile composition
- 33% and 60% of females at 12 and 15 weeks of age, respectively, exhibit needle-like crystals in the gallbladder biles
- bile cholesterol levels are decreased compared to in wild-type mice
- females exhibit a more hydrophobic bile salt pool due to lower tauro-beta-muricholate levels in bile
- gallbladder bile precipitates solid crystals, with males forming these needle-like crystals later (after 15 weeks) than females (after 12 weeks of age) and with a lower prevalence than in females
- phosphatidylcholine (PC) concentrations in the gallbladder biles are decreased, and the relative compositions shift to greater proportions of the more hydrophobic PC-(18:0-18:2) and PC-(18:0-20:4)

abnormal bile duct morphology
- 42% of 7-10 month old females, but not males, develop choledocholithiasis (bile duct stones)
- mice exhibit proliferation of bile ducts, accompanied by periportal and periductal fibrosis, resulting in fibro-obliteration and segmental strictures of bile duct

abnormal gallbladder size
- gallbladders are 3 times larger than in wild-type mice at 9 weeks of age
- over time, gallbladder size decreases in males, but not females, such that at 18 weeks of age, some males at 18 weeks of age have very small gallbladders filled with sticky mucin gel and needle-like crystals

abnormal liver morphology
- cholestatic liver damage
- mature mice develop intrahepatic stones, which are composed of needle-like crystals like the gallbladder stones

bile duct inflammation
- progressive sclerosing cholangitis

dilated bile duct
- dilated extrahepatic duct in 7 month old females

enlarged liver

gallstones
- 42% of 7-10 month old females, but not males, develop choledocholithiasis
- 50% and 80% of females at 12 and 15 weeks of age, respectively, exhibit gallstones in the gallbladder biles and by 18 weeks, all females have gallstones
- core of stones are composed of needle-like crystals and gelled mucin
- males form gallstones later, after 15 weeks of age, and with lower prevalence rates than in females
- number of gallstones per mouse ranges from 1-8 with an average of 1.3 +/- 0.3 stones per mouse and most gallstones are smaller than 0.1 mm
- stone number and size are higher in females than males

increased hepatocellular carcinoma incidence
- liver tumors are classified as hepatocellular carcinoma
- Background Sensitivity - mice on the FVB/N background show slower development of primary liver cancer compared to mice on the BALB/cAnNCrl background, showing tumors starting at 12 months of age compared to 7 months of age on the BALB/cAnNCrl background
- Background Sensitivity - tumor burden in mice on the FVB/N background is lower than on the BALB/cAnNCrl background

intrahepatic cholestasis
- occluded intrahepatic bile ducts filled with crystalline occlusions composed of needle-like crystals and mucin gel

liver cirrhosis
- Background Sensitivity - mice on the FVB/N background show slower development of cirrhosis compared to mice on the BALB/cAnNCrl background

liver fibrosis
- Background Sensitivity - collagen content in the liver of mice on the FVB/N background is lower at any time point studied compared to mice on the BALB/cAnNCrl background
- Background Sensitivity - females exhibit more severe fibrosis than males
- Background Sensitivity - fibrotic matrix in mice on the FVB/N background is cross-linked to a lesser degree than in mice on the BALB/cAnNCrl background
- Background Sensitivity - marker analysis indicates that fibrogenic cell activation is lower in mice on the FVB/N BALB/cAnNCrl background compared to the BALB/cAnNCrl background
- Background Sensitivity - mice on the FVB/N background show slower progression of liver fibrosis compared to mice on the BALB/cAnNCrl background
- mice spontaneously develop periductal onion-skin type fibrotic lesions starting from 4 weeks of age
- prominent sinusoidal fibrosis starting at 8 weeks of age

portal hypertension
- Background Sensitivity - mice on the FVB/N background show a later onset of severe portal hypertension than mice on the BALB/cAnNCrl background
- Background Sensitivity - portal pressure in mice on the FVB/N background increases at a slower pace compared to mice on the BALB/cAnNCrl background

digestive/alimentary phenotype

abnormal feces composition
- fecal acidic sterol levels are decreased 30% compared to in wild-type mice
- Normal - however, fecal neutral sterol levels are normal

endocrine/exocrine gland phenotype

abnormal bile duct morphology
- 42% of 7-10 month old females, but not males, develop choledocholithiasis (bile duct stones)
- mice exhibit proliferation of bile ducts, accompanied by periportal and periductal fibrosis, resulting in fibro-obliteration and segmental strictures of bile duct

abnormal gallbladder size
- gallbladders are 3 times larger than in wild-type mice at 9 weeks of age
- over time, gallbladder size decreases in males, but not females, such that at 18 weeks of age, some males at 18 weeks of age have very small gallbladders filled with sticky mucin gel and needle-like crystals

dilated bile duct
- dilated extrahepatic duct in 7 month old females

mammalian phenotype

homeostasis/metabolism phenotype
- Normal - mice exhibit normal plasma levels of sitosterol and campesterol

neoplasm

increased hepatocellular carcinoma incidence
- liver tumors are classified as hepatocellular carcinoma
- Background Sensitivity - mice on the FVB/N background show slower development of primary liver cancer compared to mice on the BALB/cAnNCrl background, showing tumors starting at 12 months of age compared to 7 months of age on the BALB/cAnNCrl background
- Background Sensitivity - tumor burden in mice on the FVB/N background is lower than on the BALB/cAnNCrl background

References

Smit JJ; Schinkel AH; Oude Elferink RP; Groen AK; Wagenaar E; van Deemter L; Mol CA; Ottenhoff R; van der Lugt NM; van Roon MA; van der Valk MA; Offerhaus GJ; Berns AJ; Borst P. 1993. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75(3):451-62PubMed: 8106172 MGI: J:15531

Additional References

Borst P; Schinkel AH. 1996. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer 32A(6):985-90PubMed: 8763339 MGI: J:33581
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M. 2004. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127(1):261-74PubMed: 15236191 MGI: J:93576

Additional - Abcb4^tm1Bor related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Standard PCR:Abcb4 alternate1
- Genotyping resources and troubleshooting
Breeding Considerations

The strain is maintained by mating homozygous siblings. In 1995, the donating investigator reported that homozygotes exhibit liver degeneration beginning around 8 months of age. In 2019, The Jackson Laboratory live colony also observes some incidence of sickly (jaundice) homozygotes as early as 4-5 months of age, and this occurs more frequently in females than males.
- Additional Breeding and Husbandry Support
Appearance
- albino
  Related Genotype: Tyr^c/Tyr^c
Citation
When using the MDR2 KO mouse strain in a publication, please cite the originating article(s) and include JAX stock #002539 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

AX18 (Maximum)

Pricing & Availability

Available

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Cryorecovery - Pricing

Service/Product	Description	Price
	Heterozygous and Wildtype for Abcb4<tm1Bor>

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.

Terms Of Use

General Terms and Conditions

Questions about Terms of Use

Additional Use Restrictions Apply

Notice to customers in Canada.

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As:MDR2 KO

Donating Investigator

Genetic overview

Research Applications

Base Price

Important Note

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Abcb4tm1Bor

Allele Symbol: Abcb4tm1Bor

Disease Terms

Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).

Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).

Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Genotype: Abcb4tm1Bor related

Mammalian Phenotype Terms by Genotype

Genotype: Abcb4tm1Bor/Abcb4tm1Boreither: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N)

cardiovascular system phenotype

immune system phenotype

liver/biliary system phenotype

cellular phenotype

endocrine/exocrine gland phenotype

neoplasm

reproductive system phenotype

homeostasis/metabolism phenotype

Genotype: Abcb4tm1Bor/Abcb4tm1Borinvolves: 129P2/OlaHsd * FVB/N

cellular phenotype

immune system phenotype

liver/biliary system phenotype

digestive/alimentary phenotype

homeostasis/metabolism phenotype

Genotype: Abcb4tm1Bor/Abcb4tm1BorC.129P2-Abcb4

homeostasis/metabolism phenotype

liver/biliary system phenotype

skeleton phenotype

Genotype: Abcb4tm1Bor/Abcb4tm1Borinvolves: 129P2/OlaHsd * BALB/c

cardiovascular system phenotype

immune system phenotype

liver/biliary system phenotype

Genotype: Abcb4tm1Bor/Abcb4tm1BorCAnNCrl.12P2(FVB)-Abcb4

cardiovascular system phenotype

liver/biliary system phenotype

neoplasm

growth/size/body region phenotype

hematopoietic system phenotype

homeostasis/metabolism phenotype

immune system phenotype

Genotype: Abcb4tm1Bor/Abcb4tm1BorFVB.129P2-Abcb4/J

cardiovascular system phenotype

hematopoietic system phenotype

homeostasis/metabolism phenotype

immune system phenotype

liver/biliary system phenotype

digestive/alimentary phenotype

endocrine/exocrine gland phenotype

mammalian phenotype

neoplasm

References

Additional References

Additional - Abcb4tm1Bor related

Genotyping Protocols

Breeding Considerations

Appearance

Citation

Animal Health Reports

Live Mouse

Cryorecovery - Pricing

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms Of Use

Additional Use Restrictions Apply

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Abcb4^tm1Bor

Allele Symbol: Abcb4^tm1Bor

Genotype: Abcb4^tm1Bor related

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N)

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
involves: 129P2/OlaHsd * FVB/N

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
C.129P2-Abcb4

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
involves: 129P2/OlaHsd * BALB/c

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
CAnNCrl.12P2(FVB)-Abcb4

Genotype: Abcb4^tm1Bor/Abcb4^tm1Bor
FVB.129P2-Abcb4/J

Additional - Abcb4^tm1Bor related